Agios Pharmaceuticals Reports $89.3 Million Net Loss and $8.7 Million Revenue in Q1 2025

Agios Pharmaceuticals, Inc. reported a net loss of $89.3 million for the first quarter of 2025, compared to a net loss of $81.5 million in the same period of 2024. The company's total revenue for the quarter was $8.7 million, reflecting a 6.6% increase from $8.2 million in the prior year, primarily driven by increased sales of its lead product, PYRUKYND® (mitapivat). Operating expenses rose to $115.4 million from $100.3 million, largely due to a $10.5 million increase in selling, general, and administrative expenses as the company prepares for potential regulatory approvals and commercialization efforts for PYRUKYND® in thalassemia.

The increase in operating expenses was also influenced by a $4.1 million rise in research and development costs, which totaled $72.7 million for the quarter. This increase was attributed to higher indirect expenses, particularly in compensation and related costs, as well as ongoing clinical trials for PYRUKYND® and other product candidates. The company continues to invest in its clinical pipeline, which includes ongoing studies for sickle cell disease and thalassemia, as well as the development of tebapivat for lower-risk myelodysplastic syndromes.

Agios has made strategic moves to expand its market presence, including a distribution agreement with NewBridge Pharmaceuticals to commercialize PYRUKYND® in the Gulf Cooperation Council (GCC) region. The company is also actively pursuing regulatory approvals for additional indications of PYRUKYND®, with a supplemental new drug application submitted to the FDA for thalassemia, which has a Prescription Drug User Fee Act goal date of September 7, 2025. As of March 31, 2025, Agios reported cash, cash equivalents, and marketable securities totaling $1.4 billion, which the company believes will be sufficient to fund its operations for at least the next twelve months.

Despite the positive revenue growth, Agios continues to face challenges, including significant operating losses and the need for ongoing capital to support its research and development activities. The company anticipates that it will continue to incur substantial expenses as it advances its clinical programs and prepares for potential product launches. Agios remains focused on its goal of transforming patient lives through innovative therapies for rare diseases, leveraging its expertise in cellular metabolism to develop differentiated medicines.